Featured news from NHIVNA
HIV-related news from NAM
Tenofovir during pregnancy reduces risk of mother-to-child hepatitis B virus transmission
Liz Highleyman, 2015-11-20 11:20:00
Women with chronic hepatitis B and high viral load who were treated with tenofovir (Viread) during pregnancy were significantly less likely to transmit hepatitis B virus (HBV) to their babies, according to study findings presented this week at the 2015 AASLD Liver Meeting in San Francisco. Another study showed that women with hepatitis B often experience viral load or ALT 'flares' during pregnancy or post-partum.
Calvin Pan from New York University School of Medicine and colleagues from China conducted a randomised study of the effect of tenofovir on perinatal transmission of HBV.
Prevention of mother-to-child HBV transmission is the most effective way to reduce the global burden of chronic hepatitis B infection and liver cancer, Pan said. Despite immunoprophylaxis using hepatitis B immunoglobulin (HBIG), about 10-30% of infants born to women with high HBV DNA become infected. Current World Health Organization (WHO) guidelines do not recommend antiviral therapy for hepatitis B during pregnancy.
This analysis included 200 pregnant women in five regions of China, with a mean age of 27 years. They were hepatitis B 'e' antigen (HBeAg) positive and had HBV DNA >200,000 IU/ml at baseline (mean >8 log10 IU/ml). Women who also had hepatitis C, E, delta or HIV were excluded, as were those with a history of kidney dysfunction, liver cancer or decompensated liver disease.
The women were randomly assigned (1:1) to receive either 300mg tenofovir disoproxil fumarate starting at 30-32 weeks gestation and continuing through post-partum week 4, or else no antiviral treatment. About half delivered by caesarean section. All infants received standard immunoprophylaxis using HBIG and an HBV vaccine.
Prior to delivery HBV DNA levels decreased to <200,000 IU/ml in 68% of tenofovir-treated women and 2% of untreated women. HBV serological outcomes did not differ significantly between the two groups.
At postpartum week 28, the mother-to-child transmission rate was significantly lower for infants born to tenofovir-treated women compared to untreated women, both in an intent-to-treat analysis (5.16% vs 18.0%) and in a per-protocol analysis (0% vs 6.82%).
Treatment was generally well-tolerated. Adverse events were uncommon and safety profiles were similar in the treated and untreated groups. There was no significant difference in the rate of birth defect between babies born to treated and untreated mothers (2.11% vs 1.14%); these included one case each of torticollis and umbilical hernia in the tenofovir group and one case of hypospadias in the untreated group.
"Our study demonstrates that [tenofovir] treatment during late pregnancy effectively reduced mother-to-child transmission in highly viremic mothers," the researchers concluded. "[Tenofovir] treatment was well-tolerated and resulted in a rapid viral reduction. There were no safety concerns for both mothers and infants."
They recommended that "[tenofovir] should strongly be considered for mothers whose HBV DNA levels exceeded 200,000 IU/ml and should be started at gestation week 30-32."
After the presentation, Pan was asked about the ethics of conducting a placebo-controlled study when it is already apparent that tenofovir can reduce the risk of perinatal HBV transmission. He replied that prior studies were not randomised, and said that more data confirming the safety and benefits of tenofovir are needed because many women decline to receive treatment during pregnancy due to uncertainty about its risks.
Pan was also asked about reduced bone density among children exposed to tenofovir during gestation, which has been seen in studies of women who took tenofovir for HIV treatment. He said that bone loss is difficult to determine in infants, but follow-up would continue for two years to analyse longer-term outcomes.
Source:1
